Roivant Sciences (English Wikipedia)

Henderson, Jennifer. "Changes and headcount reduction at Roivant, but hiring expected in Durham". Bizjournals. Archived from the original on 27 September 2023. Retrieved 7 January 2019.
Leuty, Ron (27 October 2016). "Biggest biotech IPO this year is a small Peninsula company". San Francisco Business Times. Archived from the original on 12 November 2016. Retrieved 14 November 2016.

bloomberg.com (Global: 99^th place; English: 77^th place)

Spalding, Rebecca (13 November 2018). "SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation". Bloomberg. Archived from the original on 28 March 2019. Retrieved 20 February 2019.
Spalding, Rebecca (13 November 2018). "SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation". Bloomberg. Archived from the original on 6 December 2018. Retrieved 5 December 2018.

clinicaltrialsarena.com (Global: low place; English: low place)

"Roivant Sciences launches Lokavant for clinical trial monitoring". Clinical Trials Arena. 14 January 2020. Archived from the original on 20 October 2020. Retrieved 1 May 2020.
Tirumalaraju, Divya (16 April 2020). "Roivant starts gimsilumab dosing in Covid-19 trial". Clinical Trials Arena. Retrieved 14 January 2024.

dcatvci.org (Global: low place; English: low place)

Arnum, Patricia Van (16 October 2019). "Emerging Pharma: Roivant Sciences on the Rise". DCATVCI. Archived from the original on 2020-06-05. Retrieved 2020-06-05.

dermavant.com (Global: low place; English: low place)

"Dermavant Sciences". Archived from the original on 2022-05-24. Retrieved 2023-02-22.

endpts.com (Global: low place; English: low place)

Carroll, John (July 17, 2018). "Vivek Ramaswamy strikes again, this time launching a Beijing-based biotech player with a pipeline". Endpoints News. Archived from the original on 2023-09-26. Retrieved 2023-09-27.
Carroll, John. "Vivek Ramaswamy is diving into RNA, launching a new biotech with Arbutus and a team of vets". Endpoints News. Archived from the original on 13 November 2018. Retrieved 31 October 2018.
Carroll, John. "Tech maven Travis May takes the helm of Roivant's data mining startup". Endpoints News. Archived from the original on 8 November 2018. Retrieved 18 November 2018.

fiercebiotech.com (Global: low place; English: 8,828^th place)

"Roivant to absorb Silicon Therapeutics with $450M-plus deal". FierceBiotech. Archived from the original on 2021-04-19. Retrieved 2021-03-25.
Taylor, Nick Paul (Jun 28, 2022). "Roivant is Pfizer's TYK2 partner". Fierce Biotech. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
Adams, Ben. "Roivant and Plexcera launch rare disease-focused spinout". Fierce Biotech. Archived from the original on 2016-10-11. Retrieved 2016-10-07.
Adams, Ben (June 7, 2017). "Roivant launches Urovant with phase 3 Merck med". FierceBiotech. Archived from the original on August 7, 2017. Retrieved August 7, 2017.
Taylor, Nick Paul. "Roivant cuts staff, reassigns others in a major reshuffle, as insider decries 'bloodbath'". Archived from the original on 2018-07-05. Retrieved 2018-07-04.

fiercehealthcare.com (Global: low place; English: low place)

Landi, Heather (June 9, 2021). "How Datavant's $7B deal with Ciox Health impacts the health data market". Fierece Healthcare. Archived from the original on 2023-03-31.

fortune.com (Global: 433^rd place; English: 284^th place)

Sonnenfeld, Jeffrey (August 31, 2023). "Smoke and mirrors: I've been debating Vivek Ramaswamy for 2 years. Here's how I got past his diversionary tactics". Fortune. Archived from the original on 2023-09-05. Retrieved 2023-09-05.
Sonnenfeld, Jeffrey; Tian, Steven (June 14, 2023). "Vivek Ramaswamy is threatening GOP heavyweights in the polls–but his business record doesn't live up to the hype". Fortune. Archived from the original on 2023-09-05. Retrieved 2023-09-05.

globenewswire.com (Global: 2,614^th place; English: 1,549^th place)

"Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis". GlobeNewswire News Room (Press release). Dermavant Sciences Inc. 2019-06-05. Archived from the original on 2019-06-12. Retrieved 2020-03-18.

newrepublic.com (Global: 1,948^th place; English: 1,153^rd place)

Aronoff, Kate (2023-02-22). "GOP Presidential Candidate Vivek Ramaswamy, Who Used to Do Business With China, Wants to Ban Business With China". The New Republic. ISSN 0028-6583. Archived from the original on 2023-09-26. Retrieved 2023-09-27.

nytimes.com (Global: 7^th place; English: 7^th place)

Weisman, Jonathan; Robbins, Rebecca; Farrell, Maureen (27 June 2023). "How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run". The New York Times. Archived from the original on 2023-06-29. Retrieved 2023-09-05.
"Roivant Begins Giving Experimental COVID-19 Drug to First U.S. Patients". The New York Times. Reuters. 2020-04-15. ISSN 0362-4331. Retrieved 2020-04-23.
Weisman, Jonathan; Robbins, Rebecca; Farrell, Maureen (2023-06-27). "How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run". The New York Times. ISSN 0362-4331. Archived from the original on 2023-06-29. Retrieved 2023-09-13. In 2014, Mr. Ramaswamy founded Roivant Sciences — incorporated in the tax haven of Bermuda and backed by nearly $100 million in funding from investors including QVT, a hedge fund that employed Mr. Ramaswamy after college.

politico.com (Global: 312^th place; English: 197^th place)

Piper, Jessica (14 May 2023). "How Vivek Ramaswamy made a fortune before pivoting to politics". Politico. Archived from the original on 2023-06-29. Retrieved 2023-09-05.

prnewswire.com (Global: 406^th place; English: 258^th place)

"Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology" (Press release). PR Newswire. May 3, 2021. Archived from the original on October 3, 2021. Retrieved October 3, 2021.
""Datavant Raises $40 Million in Series B Financing to Expand Open Health Data Ecosystem"" (Press release). Archived from the original on 2020-10-15. Retrieved 2020-10-13.

reuters.com (Global: 49^th place; English: 47^th place)

Satija, Bhanvi; Mandowara, Khushi; Satija, Bhanvi (December 1, 2022). "Roivant, Pfizer team up on inflammatory disease drug". Reuters. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
"Roche buys U.S. rights to Roivant bowel disease drug in $7.1 billion deal". Reuters. Retrieved 2024-04-05.
"Organon to buy Roivant's dermatology unit for up to $1.2 billion". Reuters. 18 September 2024.

roivant.com (Global: low place; English: low place)

investor.roivant.com

"Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus". Roivant. June 28, 2022. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
"Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases". Roivant. December 1, 2022. Archived from the original on 2023-03-31. Retrieved 2023-03-31.

roivant.com

"Roivant Company Overview". Roivant Company Website.

sec.gov (Global: 572^nd place; English: 436^th place)

"FY 2024 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 30 May 2024. Retrieved 16 June 2024.
"2023 Proxy Statement". Archived from the original on 2023-09-02. Retrieved 2023-09-02.

seekingalpha.com (Global: 5,344^th place; English: 3,420^th place)

Out of Ignorance (6 March 2023). "Roivant Sciences: Fiercely Economic Actor with Multiple Catalysts". Seeking Alpha. Archived from the original on 2023-03-31. Retrieved 2023-03-31.

techcrunch.com (Global: 187^th place; English: 146^th place)

Loizos, Connie (14 November 2018). "Biotech holding company Roivant raised $200M in funding at a whopping $7B valuation". TechCrunch. Archived from the original on 25 September 2020. Retrieved 1 May 2020.
Loizos, Connie (2018-11-14). "Biotech holding company Roivant Sciences raised $200M in funding at a whopping $7B valuation". TechCrunch. Archived from the original on 2023-04-18. Retrieved 2023-09-13.
"Roivant, which creates companies around abandoned drugs, just raised $1.1 billion from SoftBank". TechCrunch. Archived from the original on 2018-11-06. Retrieved 2018-11-06.

web.archive.org (Global: 1^st place; English: 1^st place)

"2023 Proxy Statement". Archived from the original on 2023-09-02. Retrieved 2023-09-02.
Spalding, Rebecca (13 November 2018). "SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation". Bloomberg. Archived from the original on 28 March 2019. Retrieved 20 February 2019.
"Dermavant Sciences". Archived from the original on 2022-05-24. Retrieved 2023-02-22.
Loizos, Connie (14 November 2018). "Biotech holding company Roivant raised $200M in funding at a whopping $7B valuation". TechCrunch. Archived from the original on 25 September 2020. Retrieved 1 May 2020.
Landi, Heather (June 9, 2021). "How Datavant's $7B deal with Ciox Health impacts the health data market". Fierece Healthcare. Archived from the original on 2023-03-31.
"Roivant Sciences launches Lokavant for clinical trial monitoring". Clinical Trials Arena. 14 January 2020. Archived from the original on 20 October 2020. Retrieved 1 May 2020.
Aronoff, Kate (2023-02-22). "GOP Presidential Candidate Vivek Ramaswamy, Who Used to Do Business With China, Wants to Ban Business With China". The New Republic. ISSN 0028-6583. Archived from the original on 2023-09-26. Retrieved 2023-09-27.
Keown, Alex (July 17, 2018). "Roivant Launches New China-Based Startup Sinovant Sciences". BioSpace. Archived from the original on 2023-09-26. Retrieved 2023-09-27.
Carroll, John (July 17, 2018). "Vivek Ramaswamy strikes again, this time launching a Beijing-based biotech player with a pipeline". Endpoints News. Archived from the original on 2023-09-26. Retrieved 2023-09-27.
Arnum, Patricia Van (16 October 2019). "Emerging Pharma: Roivant Sciences on the Rise". DCATVCI. Archived from the original on 2020-06-05. Retrieved 2020-06-05.
"On Heels of the Sale of Five Vants, Roivant Launches New Company Lokavant". BioSpace. Archived from the original on 2020-04-27. Retrieved 2020-03-18.
"Roivant offloads biotech stakes in $3B alliance with Japanese pharma". BioPharma Dive. Archived from the original on 2020-10-28. Retrieved 2020-06-11.
Haggin, Patience (2020-04-08). "Companies Seek to Pool Medical Records to Create Coronavirus Patient Registry". Wall Street Journal. ISSN 0099-9660. Archived from the original on 2020-06-26. Retrieved 2020-07-01.
"Roivant's Ramaswamy Steps Down as CEO, Becomes Executive Chairman". BioSpace. Archived from the original on 2021-01-26. Retrieved 2021-01-28.
"Roivant to absorb Silicon Therapeutics with $450M-plus deal". FierceBiotech. Archived from the original on 2021-04-19. Retrieved 2021-03-25.
"Roivant Dives Deeper into AI with $450 Million Buy of Silicon Therapeutics". BioSpace. Archived from the original on 2021-02-27. Retrieved 2021-03-25.
"Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology" (Press release). PR Newswire. May 3, 2021. Archived from the original on October 3, 2021. Retrieved October 3, 2021.
Taylor, Nick Paul (Jun 28, 2022). "Roivant is Pfizer's TYK2 partner". Fierce Biotech. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
"Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus". Roivant. June 28, 2022. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
"Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases". Roivant. December 1, 2022. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
Satija, Bhanvi; Mandowara, Khushi; Satija, Bhanvi (December 1, 2022). "Roivant, Pfizer team up on inflammatory disease drug". Reuters. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
Out of Ignorance (6 March 2023). "Roivant Sciences: Fiercely Economic Actor with Multiple Catalysts". Seeking Alpha. Archived from the original on 2023-03-31. Retrieved 2023-03-31.
Sonnenfeld, Jeffrey (August 31, 2023). "Smoke and mirrors: I've been debating Vivek Ramaswamy for 2 years. Here's how I got past his diversionary tactics". Fortune. Archived from the original on 2023-09-05. Retrieved 2023-09-05.
Sonnenfeld, Jeffrey; Tian, Steven (June 14, 2023). "Vivek Ramaswamy is threatening GOP heavyweights in the polls–but his business record doesn't live up to the hype". Fortune. Archived from the original on 2023-09-05. Retrieved 2023-09-05.
Piper, Jessica (14 May 2023). "How Vivek Ramaswamy made a fortune before pivoting to politics". Politico. Archived from the original on 2023-06-29. Retrieved 2023-09-05.
Weisman, Jonathan; Robbins, Rebecca; Farrell, Maureen (27 June 2023). "How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run". The New York Times. Archived from the original on 2023-06-29. Retrieved 2023-09-05.
Carroll, John. "Vivek Ramaswamy is diving into RNA, launching a new biotech with Arbutus and a team of vets". Endpoints News. Archived from the original on 13 November 2018. Retrieved 31 October 2018.
Keown, Alex. "Roivant Taps Genentech Veteran". BioSpace. Archived from the original on 13 November 2018. Retrieved 31 October 2018.
"Sumitomo Dainippon and Roivant Close Deal to Form Sumitovant Biopharma". BioSpace. Archived from the original on 2020-03-25. Retrieved 2020-03-25.
Henderson, Jennifer. "Changes and headcount reduction at Roivant, but hiring expected in Durham". Bizjournals. Archived from the original on 27 September 2023. Retrieved 7 January 2019.
"Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis". GlobeNewswire News Room (Press release). Dermavant Sciences Inc. 2019-06-05. Archived from the original on 2019-06-12. Retrieved 2020-03-18.
Adams, Ben. "Roivant and Plexcera launch rare disease-focused spinout". Fierce Biotech. Archived from the original on 2016-10-11. Retrieved 2016-10-07.
Leuty, Ron (27 October 2016). "Biggest biotech IPO this year is a small Peninsula company". San Francisco Business Times. Archived from the original on 12 November 2016. Retrieved 14 November 2016.
Pagliarulo, Ned. "Roivant, Sumitomo alliance to target cystic fibrosis gene therapy". BioPharma Dive. Archived from the original on 12 November 2019. Retrieved 12 November 2019.
Adams, Ben (June 7, 2017). "Roivant launches Urovant with phase 3 Merck med". FierceBiotech. Archived from the original on August 7, 2017. Retrieved August 7, 2017.
Carroll, John. "Tech maven Travis May takes the helm of Roivant's data mining startup". Endpoints News. Archived from the original on 8 November 2018. Retrieved 18 November 2018.
""Datavant Raises $40 Million in Series B Financing to Expand Open Health Data Ecosystem"" (Press release). Archived from the original on 2020-10-15. Retrieved 2020-10-13.
Taylor, Nick Paul. "Roivant cuts staff, reassigns others in a major reshuffle, as insider decries 'bloodbath'". Archived from the original on 2018-07-05. Retrieved 2018-07-04.
"Roivant pivots towards ARDS in COVID-19". BioCentury. Archived from the original on 2020-08-15. Retrieved 2020-04-02.
Weisman, Jonathan; Robbins, Rebecca; Farrell, Maureen (2023-06-27). "How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run". The New York Times. ISSN 0362-4331. Archived from the original on 2023-06-29. Retrieved 2023-09-13. In 2014, Mr. Ramaswamy founded Roivant Sciences — incorporated in the tax haven of Bermuda and backed by nearly $100 million in funding from investors including QVT, a hedge fund that employed Mr. Ramaswamy after college.
Loizos, Connie (2018-11-14). "Biotech holding company Roivant Sciences raised $200M in funding at a whopping $7B valuation". TechCrunch. Archived from the original on 2023-04-18. Retrieved 2023-09-13.
"Roivant, which creates companies around abandoned drugs, just raised $1.1 billion from SoftBank". TechCrunch. Archived from the original on 2018-11-06. Retrieved 2018-11-06.
Spalding, Rebecca (13 November 2018). "SoftBank-Backed Biotech Roivant Climbs to $7 Billion Valuation". Bloomberg. Archived from the original on 6 December 2018. Retrieved 5 December 2018.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Aronoff, Kate (2023-02-22). "GOP Presidential Candidate Vivek Ramaswamy, Who Used to Do Business With China, Wants to Ban Business With China". The New Republic. ISSN 0028-6583. Archived from the original on 2023-09-26. Retrieved 2023-09-27.
Haggin, Patience (2020-04-08). "Companies Seek to Pool Medical Records to Create Coronavirus Patient Registry". Wall Street Journal. ISSN 0099-9660. Archived from the original on 2020-06-26. Retrieved 2020-07-01.
"Roivant Begins Giving Experimental COVID-19 Drug to First U.S. Patients". The New York Times. Reuters. 2020-04-15. ISSN 0362-4331. Retrieved 2020-04-23.
Weisman, Jonathan; Robbins, Rebecca; Farrell, Maureen (2023-06-27). "How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run". The New York Times. ISSN 0362-4331. Archived from the original on 2023-06-29. Retrieved 2023-09-13. In 2014, Mr. Ramaswamy founded Roivant Sciences — incorporated in the tax haven of Bermuda and backed by nearly $100 million in funding from investors including QVT, a hedge fund that employed Mr. Ramaswamy after college.

wsj.com (Global: 79^th place; English: 65^th place)

Haggin, Patience (2020-04-08). "Companies Seek to Pool Medical Records to Create Coronavirus Patient Registry". Wall Street Journal. ISSN 0099-9660. Archived from the original on 2020-06-26. Retrieved 2020-07-01.

yahoo.com (Global: 38^th place; English: 40^th place)

finance.yahoo.com

"Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease". Yahoo Finance. 2023-12-14. Retrieved 2024-04-05.

Roivant Sciences (English Wikipedia)

biocentury.com (Global: low place; English: low place)

biopharmadive.com (Global: low place; English: low place)

biospace.com (Global: low place; English: 7,595th place)

bizjournals.com (Global: 407th place; English: 241st place)

bloomberg.com (Global: 99th place; English: 77th place)

clinicaltrialsarena.com (Global: low place; English: low place)

dcatvci.org (Global: low place; English: low place)

dermavant.com (Global: low place; English: low place)

endpts.com (Global: low place; English: low place)

fiercebiotech.com (Global: low place; English: 8,828th place)

fiercehealthcare.com (Global: low place; English: low place)

fortune.com (Global: 433rd place; English: 284th place)

globenewswire.com (Global: 2,614th place; English: 1,549th place)

newrepublic.com (Global: 1,948th place; English: 1,153rd place)

nytimes.com (Global: 7th place; English: 7th place)

politico.com (Global: 312th place; English: 197th place)

prnewswire.com (Global: 406th place; English: 258th place)

reuters.com (Global: 49th place; English: 47th place)

roivant.com (Global: low place; English: low place)

investor.roivant.com

roivant.com

sec.gov (Global: 572nd place; English: 436th place)

seekingalpha.com (Global: 5,344th place; English: 3,420th place)

techcrunch.com (Global: 187th place; English: 146th place)

web.archive.org (Global: 1st place; English: 1st place)

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

wsj.com (Global: 79th place; English: 65th place)

yahoo.com (Global: 38th place; English: 40th place)

finance.yahoo.com

biospace.com (Global: low place; English: 7,595^th place)

bizjournals.com (Global: 407^th place; English: 241^st place)

bloomberg.com (Global: 99^th place; English: 77^th place)

fiercebiotech.com (Global: low place; English: 8,828^th place)

fortune.com (Global: 433^rd place; English: 284^th place)

globenewswire.com (Global: 2,614^th place; English: 1,549^th place)

newrepublic.com (Global: 1,948^th place; English: 1,153^rd place)

nytimes.com (Global: 7^th place; English: 7^th place)

politico.com (Global: 312^th place; English: 197^th place)

prnewswire.com (Global: 406^th place; English: 258^th place)

reuters.com (Global: 49^th place; English: 47^th place)

sec.gov (Global: 572^nd place; English: 436^th place)

seekingalpha.com (Global: 5,344^th place; English: 3,420^th place)

techcrunch.com (Global: 187^th place; English: 146^th place)

web.archive.org (Global: 1^st place; English: 1^st place)

worldcat.org (Global: 5^th place; English: 5^th place)

wsj.com (Global: 79^th place; English: 65^th place)

yahoo.com (Global: 38^th place; English: 40^th place)